FDA Advisory Committee Backs Pfizer’s Pneumonia Vaccine for Use in Adults

by Kathy Jones on  November 17, 2011 at 8:38 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

Pfizer's pneumonia vaccine for children, Prevnar 13, has been backed by an FDA advisory committee to be used in treating diseases caused by pneumococcus bacteria in adults.
 FDA Advisory Committee Backs Pfizer’s Pneumonia Vaccine for Use in Adults
FDA Advisory Committee Backs Pfizer’s Pneumonia Vaccine for Use in Adults

The advisory committee voted 14-1 in favor of using the vaccine in adults and with FDA usually approving products backed by the committee, Prevnar is expected to be approved for treating pneumonia disease among adults.

The health regulator is said to be considering placing the vaccine on an accelerated approval process and will reach a decision soon on whether to approve the vaccine to be used in adults over 50 years of age.

The vaccine, which was approved in October 2010 for preventing diseases caused by S. pneumoniae serotypes in children, generated over $3.7 billion in sales worldwide and Pfizer revealed that it could generate an additional $1.5 billion annually if it is approved for adults.

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Hib Vaccine Pneumonia Q Fever Silicosis Respiratory Distress Syndrome Vaccination for Children Cough Symptom Evaluation Legionnaires’ disease Top 10 Vaccine Myths Debunked 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive